OBI Pharma, Inc. (TPEX: 4174)

Market Cap	17.31B
Revenue (ttm)	58.05M
Net Income (ttm)	-2.16B
Shares Out	229.25M
EPS (ttm)	-9.41
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	354,358
Open	75.30
Previous Close	75.50
Day's Range	75.30 - 76.80
52-Week Range	58.00 - 92.90
Beta	0.97
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 11, 2024

About OBI Pharma

OBI Pharma, Inc., a biopharma company, develops and licenses novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally. It offers Adagloxad Simolenin (OBI-822), a breast cancer active immunity anti-cancer drug for generating antibody against tumor surface antigen Globo H; OBI-833, an immunity anti-cancer drug for the treatment of lung cancer; OBI-866 SSEA-4, an active immune-oncology drug; OBI-888, a Globo H monoclonal antibody; OBI-999, an antibody drug conjugate; OBI-3424, a micromolecule chemotherapy prodr...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4174

Financial Performance

In 2023, OBI Pharma's revenue was 41.55 million, an increase of 781.96% compared to the previous year's 4.71 million. Losses were -1.05 billion, -35.16% less than in 2022.